Scher HI - Search Results

1

Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.

Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI. Solit DB, et al. Among authors: scher hi. Clin Cancer Res. 2007 Mar 15;13(6):1775-82. doi: 10.1158/1078-0432.CCR-06-1863. Clin Cancer Res. 2007. PMID: 17363532 Free PMC article. Clinical Trial.

2

Hormone refractory prostatic cancer: the role of radiolabelled diphosphonates and growth factor inhibitors.

Scher HI, Curley T, Yeh S, Tong W, O'Moore PV, Larson S. Scher HI, et al. Adv Exp Med Biol. 1992;324:115-29. doi: 10.1007/978-1-4615-3398-6_12. Adv Exp Med Biol. 1992. PMID: 1283494 Review. No abstract available.

3

Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.

Seidman AD, Scher HI, Petrylak D, Dershaw DD, Curley T. Seidman AD, et al. Among authors: scher hi. J Urol. 1992 Mar;147(3 Pt 2):931-4. doi: 10.1016/s0022-5347(17)37426-8. J Urol. 1992. PMID: 1371564 Clinical Trial.

4

Therapeutic alternatives for hormone-refractory prostatic cancer.

Scher HI, Curley T, Yeh S, Iversen JM, O'Dell M, Larson SM. Scher HI, et al. Semin Urol. 1992 Feb;10(1):55-64. Semin Urol. 1992. PMID: 1373515 Review.

5

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression.

Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, Reuter V, Tong WP, Iversen J, Louison C, Albino AP, et al. Motzer RJ, et al. Among authors: scher hi. Cancer Res. 1992 Oct 15;52(20):5775-9. Cancer Res. 1992. PMID: 1394202 Clinical Trial.

6

A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.

Ilson DH, Motzer RJ, Kradin RL, Vogelzang NJ, Bajorin DF, Scher HI, Nanus D, O'Moore P, Marathias K, Bosl GJ. Ilson DH, et al. Among authors: scher hi. J Clin Oncol. 1992 Jul;10(7):1124-30. doi: 10.1200/JCO.1992.10.7.1124. J Clin Oncol. 1992. PMID: 1607918 Clinical Trial.

7

Carboplatin, etoposide, and bleomycin for patients with poor-risk germ cell tumors.

Motzer RJ, Cooper K, Geller NL, Pfister DG, Lin SY, Bajorin D, Scher HI, Herr H, Fair W, Morse M, et al. Motzer RJ, et al. Among authors: scher hi. Cancer. 1990 Jun 1;65(11):2465-70. doi: 10.1002/1097-0142(19900601)65:11<2465::aid-cncr2820651112>3.0.co;2-7. Cancer. 1990. PMID: 1692505

8

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease.

Scher HI, Curley T, Geller N, Engstrom C, Dershaw DD, Lin SY, Fitzpatrick K, Nisselbaum J, Schwartz M, Bezirdjian L, et al. Scher HI, et al. J Clin Oncol. 1990 Nov;8(11):1830-8. doi: 10.1200/JCO.1990.8.11.1830. J Clin Oncol. 1990. PMID: 1700078

9

Use of adaptive control with feedback to individualize suramin dosing.

Scher HI, Jodrell DI, Iversen JM, Curley T, Tong W, Egorin MJ, Forrest A. Scher HI, et al. Cancer Res. 1992 Jan 1;52(1):64-70. Cancer Res. 1992. PMID: 1727387

10

Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors.

Seidman AD, Scher HI, Heinemann MH, Bajorin DF, Sternberg CN, Dershaw DD, Silverberg M, Bosl GJ. Seidman AD, et al. Among authors: scher hi. Cancer. 1991 Dec 15;68(12):2561-5. doi: 10.1002/1097-0142(19911215)68:12<2561::aid-cncr2820681205>3.0.co;2-g. Cancer. 1991. PMID: 1933802 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

698 results

Search Page

Filters